Art

J-GLOBAL ID：201902251102760301   Reference number：19A0781020

Engineering chimeric antigen receptor-T cells for cancer treatment

癌治療のためのキメラ抗原受容体T細胞のエンジニアリング【JST・京大機械翻訳】

Author (6)： Ye Baixin (Department of Hematology, Renmin Hospital of Wuhan University, Wuhan, China) ,  Stary Creed M. (Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, USA) ,  Li Xuejun (Department of Neurosurgery, Xiangya Hospital, Central south University, Changsha, China) ,  Gao Qingping (Department of Hematology, Renmin Hospital of Wuhan University, Wuhan, China) ,  Kang Chunsheng (Lab of Neuro-Oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Tianjin, China) ,  Xiong Xiaoxing (Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China)
Material： Molecular Cancer (Web)
Volume： 17  Issue： 1  Page： 32  Publication year： 2018 
JST Material Number： U7336A  ISSN： 1476-4598  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Intratumor heterogeneity of tu...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0781020&from=J-GLOBAL&jstjournalNo=U7336A") }}

Thesaurus term： cell transplantation ,  solid tumor ,  human(primates) ,  interstitial tissue ,  immunosuppression ,  gene manipulation ,  clone ,  tumor ,  therapy ,  tumor immunity ,  heterogeneity ,  tumor cell ,  *T cell
Semi thesaurus term： 悪性腫瘍 ,  微小環境 ,  *癌治療 , 【Automatic Indexing@JST】

Author keywords (5)： Tumor ecosystem ,  Intratumor heterogeneity ,  T-cell exhaustion ,  Cancer immunotherapy ,  Chimeric antigen receptor (CAR) T cell therapy

JST classification (2)： Chemistry,biochemistry and pathology of tumors(=neoplasms)  (GE02030N) ,  Gene expression  (EC02040Q)

Reference (131)：

• N Engl J Med; Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma; J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, S Dalle, M Schenker, V Chiarion-Sileni, I Marquez-Rodas; 377; 2017; 1824-1835; 10.1056/NEJMoa1709030; citation_id=CR1
• N Engl J Med; PD-1 and PD-L1 inhibitors as salvage therapy for urothelial carcinoma; G Sonpavde; 376; 2017; 1073-1074; 10.1056/NEJMe1701182; citation_id=CR2
• N Engl J Med; Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma; GV Long, A Hauschild, M Santinami, V Atkinson, M Mandala, V Chiarion-Sileni, J Larkin, M Nyakas, C Dutriaux, A Haydon; 377; 2017; 1813-1823; 10.1056/NEJMoa1708539; citation_id=CR3
• N Engl J Med; PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma; PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, S Berry, EK Chartash, A Daud, SP Fling; 374; 2016; 2542-2552; 10.1056/NEJMoa1603702; citation_id=CR4
• N Engl J Med; PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma; SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, SJ Schuster, MM Millenson, D Cattry, GJ Freeman; 372; 2015; 311-319; 10.1056/NEJMoa1411087; citation_id=CR5

Terms in the title (4)： 癌治療 ,  キメラ抗原受容体 ,  T細胞 ,  エンジニアリング